Cash/Burn From SEC Filing For Period: 

Q1 '20

AMRN

Amarin Corporation

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids.

Cash

$542.2M

Burn Rate

-$20.6M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Vascepa

Cardiovascular Disease / Triglycerides

ANDA Litigation

9/2/2020

Vascepa

Cardiovascular disease (triglyceride lowering)

Quarterly Sales (Approved)

November 3, 2020 (Est)

Vascepa

COVID-19

Phase 2

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

AMRN's Q2 VASCEPA® Net Sales...

AMRN reported a $135.3 million in net total revenue in Q2 2020, an increase of 34% over Q2 2019, resulting in H1 2020 net total revenue of $290.3 million, an increase of 67% over H1 2019. In addition...

AMARIN ANDA LITIGATION UPDATE:...

In our Amp Patent Investor subscription forum, I provide my analysis of the possible affect on the appellate court's ruling, of the recent scientific publication by the Reduce-It trial's principal inv...

Jackpot...

BINGO #winner #ZGNX #AMRN #AIMT...

AMRN Litigation Update | Possi...

Dr. Vacchiano, JD, PhD, analyzed the complex factual, regulatory and legal issues specifically related to Amarin's possible attempt to obtain a preliminary injunction from the court to stop a possible...

Experienced biotech patent att...

Check out my 20 minute video about the ongoing AMRN ANDA appeal. It includes valuable information include key dates in the litigation as well as the #1 misconception of biotech investors regarding thi...

AMRN Litigation Update - 5/19/...

On 5/19/20 the BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO), the largest trade organization representing biotech companies and Universities filed an amicus brief in the Amarin appeal. The brief relates...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon